Wall Street Remains Bullish On Lantheus Holdings, Inc. (LNTH)

Lantheus Holdings, Inc. (NASDAQ:LNTH) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Lantheus Holdings, Inc. (NASDAQ:LNTH) has a rating of ‘Buy’ or equivalent from almost 80% of the analysts covering the stock. With a median price target of $75, the stock has an upside potential of 18.48% from the current price.

On November 24, Matthew Taylor, an analyst at Jefferies, reiterated a Buy rating on Lantheus Holdings, Inc., while keeping the price target at $105, which suggests an upside potential of 66%.

A and N photography/Shutterstock.com

Earlier on November 12, Leerink Partners trimmed its price target on Lantheus Holdings, Inc. to $90 from $97, with an unchanged ‘Overweight’ rating. The analyst believes that 340B pricing pressures and competitive dynamics will influence the company’s Pylarify franchise, leading to a downgrade of the outlook.

When Lantheus Holdings, Inc. announced its third-quarter results on November 6, it delivered mixed financial performance. Although revenue surpassed consensus estimates by about 5%, the diluted EPS came at 2% below consensus expectations. The lower Pylarify revenues were attributed to “340B best price-driven price compression and competitive pressures from Ga-68 PSMA PET agents at large accounts.”

Lantheus Holdings, Inc. is a Massachusetts-based company specializing in diagnostic and therapeutic products for the treatment of a diverse range of diseases. Incorporated in 1956, the company offers DEFINITY, TechneLite, Xenon-133, and Neurolite, among others.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.